托伐普坦长期治疗常染色体显性多囊肾病的纵向疗效研究长期结局
本研究在杏林大学队列中筛选179例符合托伐普坦指征的常染色体显性多囊肾病患者,118例同意入组,回顾性治疗前期中位1.8年、前瞻性治疗期中位4.0年。治疗5年间log10(总肾脏体积)年斜率较治疗前下降(P<0.0001),女性估算肾小球滤过率下降改善(P<0.0001)而男性无显著改善(P=0.6321)。
要点
- 治疗5年间log10(总肾脏体积)年斜率较治疗前下降(P<0.0001)。
- 女性估算肾小球滤过率下降改善(P<0.0001),男性无显著改善(P=0.6321)。
- 第一年估算身高调整总肾脏体积生长率α降幅≥中位2.94%者估算肾小球滤过率更优。
核心结论
- 托伐普坦治疗4年间两性总肾脏体积生长率均下降。
- 男性估算肾小球滤过率斜率未见显著效果,可能因雄激素刺激囊泡生成及估算肾小球滤过率非线性轨迹纵向变化分析困难。
- 第一年估算身高调整总肾脏体积生长率α降幅较大与较好肾脏预后相关。
- 无论是否使用托伐普坦,女性血管加压素介导的水重吸收均较男性更活跃。
研究设计与样本
- 来自杏林大学队列的纵向疗效研究,调查299例患者,179例符合托伐普坦指征(总肾脏体积≥750 ml、总肾脏体积斜率≥5%/年、估算肾小球滤过率≥15 ml/min/1.73 m2),其中118例同意入组。
- 回顾性治疗前期中位1.8年,前瞻性治疗期中位4.0年。
主要发现
- 治疗5年间log10(总肾脏体积)年斜率较治疗前下降(P<0.0001)。
- 估算身高调整总肾脏体积生长率α(eHTKV-α,%/年)较基线下降(P<0.0001)。
- 女性估算肾小球滤过率下降改善(P<0.0001),男性无显著改善(P=0.6321)。
- 治疗5年间,第一年eHTKV-α较基线降幅≥中位2.94%组估算肾小球滤过率显著优于降幅<2.94%组。
- 无论治疗如何,男性游离水清除率高于女性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The effects of long-term and uninterrupted tolvaptan treatment on autosomal dominant polycystic kidney disease (ADPKD) are unclear. Therefore, a more than 3-year continuous treatment study was performed. METHODS: From the Kyorin University cohort, 299 patients were surveyed and 179 patients were indicated for tolvaptan having a total kidney volume (TKV) ≥750 ml, TKV slope ≥5%/yr, and estimated glomerular filtration rate (eGFR) ≥15 ml/min per 1.73 m2. Among 179 patients, 118 patients consented to the study. RESULTS: Retrospective pretreatment and prospective on-treatment periods had a median of 1.8 and 4.0 years, respectively. During the 5 treatment-years, the log10(TKV) slope/yr decreased from the pretreatment period (P < 0.0001) and the estimated height-adjusted TKV growth rate α (eHTKV-α, %/yr) decreased from baseline (P < 0.0001). The decline in eGFR improved in female patients (P < 0.0001), but not in males (P = 0.6321). Furthermore, during the 5 treatment-years, eGFR remained significantly better in the group with a percent decrease in eHTKV-α from baseline to the first treatment-year ≥ the median (2.94%) than in the group with a decrease <2.94%. The free-water clearance was higher in males than in females irrespective of treatment. CONCLUSION: The TKV growth rate decreased in 4 years with tolvaptan in both sexes. The insignificant effects of tolvaptan on the eGFR slope in males were likely due to androgen stimulation of cystogenesis and analytical difficulty of longitudinal changes in nonlinear trajectories of eGFR. The larger decrease in eHTKV-α in the first year was related to a better renal prognosis. The vasopressin-mediated water reabsorption was activated more in females than males irrespective of tolvaptan administration.
引用
- Higashihara E, Nutahara K, Itoh M, et al. Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD. Kidney Int Rep. 2021. PMID: 35155866. doi:10.1016/j.ekir.2021.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。